Immunotherapeutics' Tedopi vaccine has shown effectiveness in reducing death rates in some lung cancers, the company said in a statement Monday.
Lung cancer is the leading cause of cancer-related deaths in Europe and the US.
The results of a phase 3 clinical trial to assess the vaccine's therapeutic benefits were published in the journal Annals of Oncology.
According to the US Cancer Institute, the vaccine was administered to patients with advanced non-small cell lung cancer (NSCLC or adenocarcinoma), the most common type of lung cancer and one that is "usually less responsive to chemotherapy and radiation therapy radiant".
41% reduction in risk of death
A total of 219 patients, all of whom had shown resistance to other treatments, participated in the study in nine European countries and the United States. There were 139 patients who received the vaccine and 80 who received chemotherapy.
Patients who received Tedop showed a significantly higher survival rate and a better quality of life than those who received chemotherapy.
